FOXO Technologies Inc.

FOXO Technologies CEO Seamus Lagan issued a mid-year update to shareholders, highlighting first-half 2026 achievements and growth plans. The company reported net revenues of approximately $5.1 million for the first quarter of 2026, up from $3.2 million a year earlier, and narrowed its loss from operations to $0.3 million from $1.5 million. FOXO resolved several legacy liabilities, including exchanging about $7.8 million in stated value of Series A Convertible Preferred Stock into non-convertible debt to reduce potential dilution, and entered an agreement with former CEO Jon Sabes to license its epigenetics intellectual property for a 3% royalty on net revenues up to $1.3 million. The company is considering an uplisting to NYSE American or another exchange before year-end and is evaluating acquisitions, including one that could add over $10 million in annual revenues to its Vector BioSource subsidiary. Myrtle Recovery Centers is operating at near full capacity with a 92% occupancy rate and plans to add two beds, while Scott County Community Hospital continues to generate approximately 80% or more of FOXO's revenue.